Table I.

Features of study participants (n = 57)

Age (years)	11.0 (8.0–15.0)
Sex (male/female)	38:19
BMI percentile	73.1 (48.2–97.5)
FEV1 % predicted	96.6 (89.6–106.5)
FEV1/FVC	0.85 (0.79–0.89)
% Change FEV1 after bronchodilator	6.4 (3.8–8.6)
% Corticosteroids*	70
% Inhaled corticosteroids	70
% Oral corticosteroids	5
% Parenteral corticosteroids	0
% Long-acting β-agonists	32
% Leukotriene receptor antagonist	54
% Omalizumab	0
Total WBC × 106	6.9 (6.5–8.1)
% Neutrophil	53.1 (40.4–65.4)
% Eosinophil	2.0 (1.0–3.7)
% Lymphocyte	34.1 (26.3–46.5)
% Monocyte	7.6 (5.6–9.8)
% Basophil	0.4 (0.3–0.8)
IgE (IU/mL)	105.7 (3.6–520.5)
Positive allergy skin test†	64%
ACQ6score
At baseline‡	0.50 (0.17–1.08)
At follow-up	0.33 (0.17–1.50)
Asthma exacerbation by follow-up, %§	36
ED visit, %	5
Unexpected clinician visit, %	7
Unexpected clinician phone call, %	11
Corticosteroid burst, %	9
None of the above, %	23
BrTyr (ng/mg creatinine)	0.12 (0.00–0.31)
NO (ppb)	9.1 (6.0–19.8)

WBC, white blood cell; ED, emergency department.

Data are presented as median (interquartile range) unless otherwise specified.

^*Including inhaled, oral, and parenteral routes of administration.

^†Positive allergy skin test result is defined as an atopic response to at least two allergens assessed on allergy skin testing.

^‡ACQ6 scores are calculated as the mean of six individual item scores, each graded on a Likert scale ranging from zero to six. Baseline refers to the time of marker collection; follow-up refers to 6 weeks after baseline.

^§Asthma exacerbation is defined as an acute decompensation of asthma control resulting in an emergency department visit, unexpected doctor’s appointment or phone call, or oral or parenteral corticosteroid burst, or as an acute onset of asthma-related respiratory symptoms per self-report.